Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007873 · ClinicalTrials.gov registry record · Phase 2
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
A Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05007873 is a Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants, below the 903-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05007873, a Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
Conditions Studied
Interventions
- DRUG Decitabine and Cedazuridine
- DRUG Dasatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007873
The ClinicalTrials.gov registry entry for NCT05007873 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 903-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (92% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Philadelphia Chromosome Positive appearing as the primary indexed condition, and to 2 interventions - of which Decitabine and Cedazuridine is the first listed.
NCT05007873 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05007873 about?
NCT05007873 is a clinical study titled "ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase". This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherap...
What is the current status of trial NCT05007873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-10-21. Estimated completion is 2026-10-30.
What conditions does trial NCT05007873 study?
This clinical trial studies the following conditions: Philadelphia Chromosome Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive.
What interventions are being tested in trial NCT05007873?
The interventions under investigation include: Decitabine and Cedazuridine (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT05007873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05007873 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Philadelphia Chromosome Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RECRUITING · Phase 2
-
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
COMPLETED · Phase 2
Explore more on PlainTrial
Philadelphia Chromosome Positive
All registered trials for this condition
Chronic Phase Chronic Myelogenous Leukemia
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.